From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?

Author(s): Koramit Suppipat, H. Daniel Lacorazza

Journal Name: Current Cancer Drug Targets

Volume 14 , Issue 5 , 2014

Become EABM
Become Reviewer
Call for Editor


The extensive use of the same chemotherapeutics over several decades has resulted in a growing incidence of chemoresistant cancer cells and secondary malignancies. Therefore, there is an increasing need for new drugs to treat high-risk cancer patients with a higher selectivity for cancer cells and lower toxicity to normal cells. Sulforaphane is released upon hydrolysis of glucoraphanin, a constituent of cruciferous vegetables, by myrosinases that are present in the plant or intestinal microbes. Despite a large number of studies describing the chemopreventive and chemotherapeutic properties of sulforaphane in solid tumors, there is little information on the properties of sulforaphane in hematological malignancies. In this review, we discuss the anti-carcinogenic properties of sulforaphane, the need of higher doses than dietary intake, and the challenges related to testing sulforaphane as an adjunctive agent in combination with the current standard of care for frontline blood cancer.

Keywords: Animal model, cancer, clinical trial, leukemia, natural product, sulforaphane, therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 30 June, 2014
Page: [434 - 445]
Pages: 12
DOI: 10.2174/1568009614666140521142950
Price: $65

Article Metrics

PDF: 25